AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04172064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myocardial perfusion scintigraphy
Study NCT01752712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBSST + Oxytocin
Description: The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
Study NCT01752712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBSST + Placebo
Description: Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
Study NCT03127800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Description: 5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
Study NCT00375869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbeopoetin
Description: The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
Study NCT00375869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
Study NCT01850433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet based CBT for body dysmorphic disorder
Study NCT01794169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT01794169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA
Study NCT03008330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study NCT00353015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
Study NCT00353015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
Study NCT00358579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: 1 mg
Study NCT00697580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
Study NCT00358579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: 40 IU
Study NCT02402231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab is the treatment during oral immunotherapy with peanuts as protection
Study NCT01925820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys&Entecavir
Description: 180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
Study NCT01925820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys&Entecavir
Description: 180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
Study NCT00697580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training & Nutrition
Description: Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
Study NCT00697580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training & Nutrition
Description: Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
Study NCT04358601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triathlon PS Knee System with all-polyethylene tibial components
Description: Primary Total Knee Replacement
Study NCT04358601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PS Knee System with metal-backed modular components
Description: Primary Total Knee Replacement
Study NCT01283243 — intervention group
Intervention type: DEVICE
Intervention: Acoustic radiation force impulse imaging
Description: Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
Study NCT01283854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised home-based exercise
Description: Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard).
Study NCT03081078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer support
Description: Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.
Study NCT03081078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
Study NCT02927067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants will receive 400 mg of maribavir BID orally.
Study NCT02927067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Participants will receive valganciclovir tablets orally.
Study NCT02927067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo tablets matched to either maribavir or valganciclovir.
Study NCT02927067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo tablets matched to either maribavir or valganciclovir.
Study NCT04552262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: Single dose of 90 mg BAY2327949
Study NCT04552262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo to BAY 2327949
Study NCT04475809 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: group C
Description: laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
Study NCT04475809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group L
Description: laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
Study NCT04475809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group LR
Description: the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
Study NCT04475809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group LS
Description: the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
Study NCT00988767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
Study NCT02404532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIND1 System
Description: Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
Study NCT04059809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 \~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
Study NCT04111367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seraprevir
Description: Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
Study NCT04111367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
Study NCT01688648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Description: a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
Study NCT01688648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
Study NCT01379586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4053
Description: Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
Study NCT01379586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
Study NCT01363895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous closure of LAA
Description: Percutaneous closure of LAA
Study NCT01363895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation of AF
Description: Catheter ablation of AF
Study NCT01464697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone
Description: 300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
Study NCT01464697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
Study NCT03341403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotical®/Bactecal®
Description: Probiotical/Bactecal® is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill.
Study NCT03341403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pills containing placebo
Study NCT03016715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 2%
Study NCT03016715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT02448823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mass media and Stylish Events
Description: 1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~2. Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses.
Study NCT02448823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass Media
Description: 1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
Study NCT03691558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
Study NCT03691558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western Diet
Description: total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
Study NCT03123523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography at T0
Study NCT03123523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise test
Study NCT03123523 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological assays
Description: Creatinin, hematocrit and BNP assays
Study NCT03123523 — intervention group
Intervention type: DEVICE
Intervention: MRI with contrast agent injection
Description: With injection of gadolinium
Study NCT03123523 — intervention group
Intervention type: DEVICE
Intervention: MRI without contrast agent injection
Description: Without injection of gadolinium
Study NCT03123523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography at M24
Study NCT03183921 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No Interventions
Study NCT03531229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Lu AF76432 oral solution
Study NCT03531229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF76432
Description: Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
Study NCT02125760 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT)
Description: Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
Study NCT02125760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity IMT
Description: High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
Study NCT03979261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: evolution of sex ratio according to age
Description: Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
Study NCT03808519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n3 PUFA-enriched fish oil
Description: 3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
Study NCT03350477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT03350477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT03350477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT03350477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT02333929 — intervention group
Intervention type: DEVICE
Intervention: STA- Rivaroxaban Calibrator&Control
Description: One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
Study NCT03808519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Organic Sunflower Oil 5000mg per day
Study NCT00674934 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study NCT00565500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: celecoxib capsules 200 mg bid for 1 week
Study NCT00565500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: ibuprofen tablets 600 mg tid for 1 week
Study NCT00565500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules tid for 1 week
Study NCT00377299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
Study NCT00377299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active medication in all other physical aspects
Study NCT03033108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat
Description: Once daily, tablet for oral administration
Study NCT04317222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCRRT
Description: eCRRT was define as:~1. Initiated within the first 24 post-transplant hours;~2. High volume (35-50ml/kg) hemofiltration;~3. Continuous at least 12 hours per day for 3 days;~4. Standard treatment
Study NCT02482220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Study NCT00693355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium butyrate
Description: sodium butyrate
Study NCT00693355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl
Study NCT01656616 — intervention group
Intervention type: DRUG
Intervention: Cyanide antidote administration
Study NCT02275572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention
Study NCT01471574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks